908 Devices (NASDAQ:MASS) vs. Imris (OTCMKTS:IMRSQ) Financial Contrast

908 Devices (NASDAQ:MASS) and Imris (OTCMKTS:IMRSQ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Earnings & Valuation

This table compares 908 Devices and Imris”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
908 Devices	$57.80 million	5.71	$19.49 million	($1.00)	-8.73
Imris	N/A	N/A	N/A	N/A	N/A

908 Devices has higher revenue and earnings than Imris.

Analyst Recommendations

This is a breakdown of recent recommendations for 908 Devices and Imris, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
908 Devices	1	0	1	0	2.00
Imris	0	0	0	0	0.00

908 Devices currently has a consensus target price of $12.00, indicating a potential upside of 37.46%. Given 908 Devices’ stronger consensus rating and higher possible upside, equities analysts plainly believe 908 Devices is more favorable than Imris.

Institutional & Insider Ownership

88.1% of 908 Devices shares are held by institutional investors. 28.2% of 908 Devices shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares 908 Devices and Imris’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
908 Devices	-62.40%	-14.03%	-10.40%
Imris	N/A	N/A	N/A

Summary

908 Devices beats Imris on 6 of the 9 factors compared between the two stocks.

About 908 Devices

908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

About Imris

IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.